People and collaborations

She leads the research group Clinical HIV Epidemiology and Comorbidity at KI and is director of InfCareHIV, the Swedish national HIV quality register. Her research combines national register data with prospective studies to examine cancer and other comorbidities in people with HIV, with a particular focus on HPV-related cancer. She contributes to the Swedish national HIV treatment guidelines.

She leads the Global and Sexual Health (GloSH) research group at KI. Her research focuses on HIV prevention and care among migrants, young people and other key populations, and includes doctoral work on HPV and anal lesions in people with HIV.

She is an expert on late HIV diagnosis and missed opportunities for testing, including when migrants acquire HIV in relation to arrival in Sweden. Her research covers HIV testing, barriers to care and health outcomes in women with HIV.

Site coordinator.

His research focuses on HIV in the central nervous system, including blood and cerebrospinal fluid biomarkers of neuronal injury, and on COVID-19.

She leads the research group Women and HIV at Sahlgrenska University, which studies pregnancy and breastfeeding, treatment outcomes in women using the national InfCareHIV register, bone health after menopause, and sexual health in women with HIV.

Site coordinator.

She is a member of the national working group (NaCx) and the national expert group (NKCx) for cervical cancer prevention. Her doctoral thesis (Karolinska Institutet, 2024) evaluated prevention of cervical and vaginal cancer across the screening chain, from primary screening and colposcopy to treatment and follow-up.

His research has focused on colorectal surgery and perioperative care, and he is part of the international Enhanced Recovery After Surgery (ERAS) research collaboration. He has co-authored the Ersta studies of high-resolution flexible endoscopy of the anal canal.

His doctoral research at Uppsala University focused on high-resolution flexible endoscopy for detecting, treating and screening for HPV-related anal precancer, including underwater detection and resection of anal lesions. His interests include optical diagnosis, image-enhanced endoscopy and endoscopic resection.

She leads the clinical process for cervical dysplasia and vulvar lesions at the hospital and is secretary of the working and reference group for cervical cancer prevention (C-ARG) of the Swedish Society of Obstetrics and Gynaecology. Her research covers cervical precancer and cancer in pregnancy, HPV and preterm delivery, and audits of cervical screening.

She has led the development of the Swedish national cervical screening guidelines and worked on the national strategy for faster elimination of cervical cancer, which gives her direct experience of translating evidence into organised screening. Her research covers risk-based screening and the introduction of extended HPV genotyping and self-sampling in organised screening. She chaired the International Cancer Screening Network 2024–2026.

She has long experience of HPV detection and genotyping in cell and tissue samples, including nationwide HPV typing of cervical cancers in Sweden and laboratory work for HPV vaccination studies.

Her research uses Swedish registers and biobanks to study HPV and cervical cancer, with a focus on biomarkers for new screening tests. She works on DNA methylation tests for cervical, endometrial and ovarian cancer, including the WID-qCIN test, and has studied deep sequencing of HPV16 and cell-free HPV DNA in blood in cervical cancer.

Her research evaluates and improves cervical screening, including screening of older women and the clinical use of DNA methylation testing. She leads projects funded by the Swedish Cancer Society and the Swedish Research Council on introducing the WID-qCIN methylation test in Swedish screening.

He has held leading roles in Swedish clinical cytology, including in the Swedish Society for Clinical Cytology and the Equalis advisory group for cervical cancer prevention, and has contributed to the national guidelines for cervical cancer prevention.

Her research evaluates HPV vaccination in Sweden, including its effect on invasive cervical cancer and on vulvar and vaginal lesions, sex-neutral vaccination, and risk prediction for cervical disease. She leads a population-based evaluation of HPV genotype and cycle threshold values for risk stratification in cervical screening.

He has worked as a biostatistician in Sweden, Australia, New Zealand and the United Kingdom. His research covers natural history and microsimulation models for cancer screening, cost-effectiveness analysis, and time-to-event and multi-state models. He has led cost-effectiveness studies of prostate cancer screening, works on natural history modelling for cervical screening, and develops open-source statistical software.

He has broad experience of register-based studies and prediction models, has co-authored guidance on statistical methods and reporting for biomedical journals, and has worked with the research group on HIV register studies for many years.

His work forms much of the international evidence base on anal cancer, including meta-analyses of HPV types from infection to cancer by sex and HIV status, pooled analyses of anal HPV and precancer in women, and the anal cancer risk scale used in the IANS screening guidelines. He has also led work on the global burden of infection-related cancer and on a blood test for early detection of anal cancer.

She holds a master's degree in public health sciences from Karolinska Institutet (2025), and her doctoral project is based on the SANCA study.